Best practices for managing and analyzing large-scale genomic data in medical research

Published June 20, 2026  |  Last updated August 10, 2026

A single whole-genome sequencing run now produces more raw sequence than the entire Human Genome Project assembled across thirteen years of work, and that volume is exactly why large-scale genomic data has become a genuine bottleneck for medical research teams preparing a manuscript. The 1000 Genomes Project reconstructed the genomes of 2,504 individuals across 26 populations and still only catalogued a reference set of common variation, about 88 million variants in total, comprising 84.7 million single nucleotide polymorphisms, 3.6 million short insertions and deletions, and 60,000 structural variants (Auton et al., 2015). Multiply that scale across a modern biobank of a million participants, and the storage, quality control, and data-sharing decisions a research team makes before submission start to shape whether reviewers trust the results at all.

Genomic medicine has moved past small candidate-gene studies into population-scale sequencing, a shift Francis Collins and Harold Varmus framed in their 2015 proposal for a national Precision Medicine Initiative built on genomic, environmental, and lifestyle data linked at scale (Collins & Varmus, 2015). Getting that link right, from raw sequencer output to a submission-ready dataset, now depends on decisions about file formats, storage architecture, quality control, de-identification, and repository policy that most wet-lab-trained authors never learned in graduate school. Below is a practical walk-through of the practices that keep a genomic dataset usable, auditable, and compliant with funder policy from generation through publication.

Key Takeaways

• The 1000 Genomes Project sequenced 2,504 individuals from 26 populations, cataloguing roughly 88 million variants as a reference for human genetic variation (Auton et al., 2015)
• The All of Us Research Program’s first major genomic release covered 245,388 clinical-grade genome sequences and identified more than 1 billion genetic variants, over 275 million of them previously unreported (Bick et al., 2024)
• Standardized file formats, FASTQ for raw reads, BAM or CRAM for alignments, and VCF for variant calls, keep sequencing data usable across pipelines and institutions
• Genomic data cannot be truly anonymized, only de-identified and access-controlled, because the sequence itself is inherently identifying and can implicate relatives who never consented
• NIH’s Genomic Data Sharing Policy requires large-scale human genomic studies it funds to register in dbGaP and submit a data use certification alongside the data itself

What Counts as Large-Scale Genomic Data in Medical Research Today

Three sequencing modalities generate most of the genomic data medical researchers now submit alongside a manuscript. Whole-genome sequencing reads essentially the entire 3.2 billion base pair human genome and typically yields somewhere between three and five million variants per individual relative to a reference genome. Whole-exome sequencing restricts that read to the roughly one to two percent of the genome that codes for protein, cutting cost and file size while still returning 20,000 to 30,000 variants per sample. RNA sequencing measures gene expression rather than DNA sequence directly and commonly produces tens of millions of short reads per sample library.

Population-scale programs illustrate what “large” now means in practice. The All of Us Research Program released clinical-grade genome sequences for 245,388 participants in its first major genomic data drop, with 77 percent of participants drawn from communities historically under-represented in biomedical research and 46 percent from under-represented racial and ethnic minorities. Across that cohort the program identified more than 1 billion genetic variants, including over 275 million that had never been reported before and 3.9 million with coding consequences (Bick et al., 2024). A dataset at that scale cannot be managed the way a single-lab candidate-gene study was managed a decade ago, and reviewers at genomics-adjacent journals increasingly expect authors to describe their pipeline in the methods section, not just their findings in the results. Researchers running genome-wide association studies on cohorts of this size, and readers who want the statistical side of that pipeline, can find a fuller treatment in our guide to statistical methods in genomics, from GWAS to gene expression analysis.

File Formats That Standardize Large-Scale Sequencing Data

Raw output from a sequencer is nearly useless to anyone outside the lab that generated it unless it follows a small set of shared file formats. FASTQ stores the raw base calls and per-base quality scores coming directly off the sequencer. Alignment tools map those reads against a reference genome and write the result to SAM format or its compressed binary equivalent, BAM. CRAM compresses that same alignment data further by referencing the genome sequence itself rather than storing every base twice, cutting storage costs by roughly 30 to 60 percent relative to BAM for typical whole-genome data when configured correctly, without losing clinically relevant information. Variant Call Format, VCF, then records the specific positions where a sample differs from the reference genome, along with genotype calls and quality metrics, and has been the shared format underpinning public variant catalogs since the original 1000 Genomes Project release (Auton et al., 2015).

Adopting these formats consistently matters more than chasing the fastest aligner. A manuscript that reports variants without specifying the reference genome build, the variant caller and version used, and the quality filters applied gives reviewers and downstream users no way to reproduce the result or merge it with other datasets. Our team sees this gap often enough in advanced biostatistical methods for genomic data analysis that it is worth treating as a checklist item rather than an afterthought during manuscript preparation.

Best Practices for Storing and Computing on Large-Scale Genomic Data

On-premises storage for a large sequencing cohort quickly becomes impractical once a project moves past a handful of genomes, since a single 30x-coverage whole genome in FASTQ format runs 90 to 120 gigabytes uncompressed. Cloud and shared high-performance computing platforms have become the default response. Analysis-ready platforms such as the UK Biobank Research Analysis Platform, AnVIL, Terra, and DNAnexus keep the data in place and bring compute to it instead of requiring every collaborating site to download a full copy, which also simplifies compliance since the raw controlled-access files never leave a governed environment.

Distributed computing frameworks extend that same logic to the analysis step itself. Sparkhit, built on Apache Spark, distributes genomic data processing tasks such as read alignment and k-mer counting across a compute cluster and was benchmarked against established single-node tools on real sequencing datasets, showing substantial runtime improvements for large metagenomic and genomic workloads while remaining compatible with standard file formats (Huang, Krüger, & Sczyrba, 2018). Investigators analyzing UK Biobank’s whole-genome sequencing release have applied a similar cloud-native strategy, running fine-mapping and machine-learning variant classification for coronary artery disease risk loci directly on the platform’s cloud infrastructure rather than exporting hundreds of terabytes of sequencing data to a local cluster (Sng et al., 2025). For a broader look at the infrastructure choices behind these pipelines, see our guide to big data analytics in research.

Falling sequencing costs have made this scale routine rather than exceptional. The National Human Genome Research Institute estimates that generating a second reference human genome using the technology available when the Human Genome Project finished in 2003 would have cost roughly 50 million dollars, a figure that fell below 1,500 dollars per genome by late 2015 and has continued to decline since as platforms have moved to higher-throughput short-read chemistry (NHGRI, 2021). That trajectory is exactly why a single study can now recruit thousands of participants for whole-genome sequencing where it once could only afford a few dozen.

Quality Control and Validation Before You Submit Genomic Findings

Sequencing depth and base-calling accuracy set the ceiling for everything a study can credibly claim about a genome, so quality control has to happen before variant interpretation starts, not after. The Medical Genome Initiative, a consortium of clinical genomics laboratories across the United States and Canada, published consensus recommendations covering test validation, reference standard selection, and performance metrics specifically for clinical whole-genome sequencing aimed at diagnosing suspected germline disease, addressing a gap the group identified in prior guidance that focused mainly on targeted gene panels and exome sequencing (Marshall et al., 2021).

A useful discipline borrowed from that clinical validation work is treating variant calling as a multi-stage pipeline rather than a single step. Read alignment quality, per-base quality scores, coverage uniformity across the region of interest, and concordance with an orthogonal method such as Sanger sequencing for candidate findings all need to be checked and reported, not assumed. The All of Us Research Program’s own genomic quality process, which underpinned the release of 245,388 clinical-grade sequences, applied joint variant calling across the full cohort together with standardized concordance checks against reference materials before any dataset reached investigators (Bick et al., 2024), a scale of quality assurance worth emulating in miniature even for a single-site study of a few hundred participants.

Linking Genotype and Phenotype Through Electronic Health Records

Genomic data earns its clinical and scientific value only once it connects to phenotype, and the Electronic Medical Records and Genomics Network built the template most large linkage projects still follow. Assembled by the National Human Genome Research Institute starting in 2007, the eMERGE Network combined DNA biorepositories from multiple United States medical centers with electronic health record data and, by its second funding cycle, had shown that EHR-derived phenotypes could replicate known genotype-phenotype associations across independent sites while also enabling discovery work that a single-site registry could not support on its own (Gottesman et al., 2013).

Three practical habits make that kind of linkage usable in a manuscript. Phenotype definitions need version-controlled, algorithmic criteria rather than free-text chart review, so another site can apply the same definition to its own records. Genomic and clinical identifiers need a secure crosswalk that keeps direct identifiers out of the working analysis dataset while still allowing authorized re-linkage for cleaning or validation queries. Consent language needs to explicitly cover secondary use for the specific linkage a study performs, since a biobank consent written for a single disease area does not automatically extend to a broader EHR-genomics linkage years later.

Why Genomic Data Cannot Be Anonymized the Way Other Health Records Can

Stripping a spreadsheet of names and medical record numbers is often enough to de-identify ordinary clinical data, but a genome behaves more like a fingerprint than a spreadsheet, and the same trick does not work. A raw genetic sequence is inherently identifying because it is unique to an individual, with the partial exception of identical twins, and given a reference database it can in principle be matched back to a named person through techniques such as familial searching, the same approach investigators have used to identify suspects in forensic cold cases from distant relatives’ consumer DNA test results. Removing a participant’s name from a VCF file does not remove that risk, because the variants themselves carry enough information to re-identify the person they came from.

Researchers in Japan studied attitudes toward this exact problem, and their findings extend the concern beyond the individual participant. Takashima and colleagues, working with cancer patients and healthy volunteers recruited through Japanese research institutions, reported that participants were often more worried about privacy implications for their blood relatives, who share overlapping genetic information but never consented to anything, than about their own personal exposure. Takashima’s team recommended that consent and data-sharing policies explicitly address this family-level risk rather than treating genomic consent as a purely individual decision (Takashima et al., 2018). Family-level exposure is a large part of why every major funder now mandates controlled access rather than open, de-identified release for individual-level genomic data by default, a distinction our guide to data anonymization techniques for protecting participant privacy covers in more depth for non-genomic datasets.

Controlled-Access Repositories and the NIH Genomic Data Sharing Policy

NIH’s Genomic Data Sharing Policy requires that any large-scale human genomic study it funds register in the database of Genotypes and Phenotypes, dbGaP, and submit both the underlying data and a data use certification specifying the approved research purposes for that dataset. NIH last updated that policy page in August 2025, and it remains built around this dbGaP-centered controlled-access model. Individual-level genotype and sequence data sit behind a data access committee review, while aggregate genomic summary results are typically released with fewer restrictions so other investigators can evaluate whether a dataset is relevant to their own work before applying for controlled access.

That policy has a track record long enough to show what it actually does in practice. An analysis of the earlier GWAS Data Sharing Policy, the direct predecessor to today’s GDS Policy, found that dbGaP had granted more than 2,200 investigators access to controlled genomic datasets within its first several years, evidence that a controlled-access model can scale to real secondary-use demand rather than simply locking data away (Paltoo et al., 2014). dbGaP’s own data browser later added view-only access to variant-level summary information without requiring a full data access application, lowering the barrier for a researcher who just needs to check whether a dataset contains a variant of interest before committing to the full application process (Wong et al., 2017).

Outside the United States, similar controlled-access logic underpins the European Genome-phenome Archive and national frameworks built on the Global Alliance for Genomics and Health’s Beacon protocol, which lets a researcher query whether a specific variant exists anywhere in a federated network of datasets without downloading or even seeing the underlying genotype data. Portugal’s national Beacon implementation, built to interoperate with the European 1+ Million Genomes initiative, illustrates the current approach, exposing enough metadata to make a dataset discoverable while keeping individual-level genotypes behind a formal access request, a design chosen specifically to balance discovery against re-identification risk from variant-level queries (Oliveira et al., 2026).

That same tension between openness and protection looks different across regions with less established genomic infrastructure. Researchers coordinating Africa’s H3Africa consortium described persistent gaps in local sequencing capacity, bandwidth for transferring large sequencing files, and harmonized ethics review across partner countries, arguing that data-sharing policy modeled on well-resourced repositories can inadvertently disadvantage the very populations a global genomics initiative sets out to include (Mulder et al., 2017).

What Authors Should Report When a Manuscript Depends on Genomic Data

Reviewers at genomics-adjacent journals increasingly reject or return manuscripts for gaps that have nothing to do with the biological finding itself. A methods section needs to name the reference genome build, the aligner and variant caller with version numbers, the quality filters applied to variant calls, and the repository plus accession number where raw or processed data were deposited. A data availability statement needs to specify whether access is open or controlled and, if controlled, which committee reviews requests and roughly how long that review takes, since editors increasingly ask authors to confirm data will be available to reviewers, not only to readers, before acceptance.

Common mistakes that show up repeatedly across genomic manuscripts include citing a reference genome build inconsistently between the methods section and a supplementary table, omitting the variant caller version even though different versions of the same tool can call different variants from identical raw reads, and describing a dataset as anonymized when it is genomic and therefore only de-identified and access-controlled rather than truly anonymous. Each of these gaps is straightforward to fix before submission, and catching them early is far cheaper than answering a reviewer’s methodological objection after months in peer review. Editors on our manuscript writing team flag exactly this class of gap during pre-submission review, well before a genomic methods section ever reaches a journal editor.

Where Large-Scale Genomic Data Management Is Headed Next

Federated analysis is replacing centralized data transfer as the default model for multi-site genomic studies. Instead of shipping raw sequencing files between institutions, a growing number of consortia now ship the analysis query to wherever the data already sits, an approach the GA4GH Beacon v2 specification formalizes by standardizing how a request for a specific variant, sample, or phenotype combination gets sent to and answered by a remote dataset without exposing individual-level records (Oliveira et al., 2026).

Machine learning is also changing which parts of variant interpretation still need a human in the loop. Comparative work on the UK Biobank’s whole-genome sequencing release found that machine-learning classifiers could match or exceed conventional fine-mapping tools at pinpointing the most likely causal variant within a disease-associated locus, while still requiring the same provenance tracking, version control, and orthogonal validation that any other variant-calling pipeline needs before a finding is trusted (Sng et al., 2025). Two-sample designs built on published genome-wide association study summary statistics increasingly feed directly into causal-inference methods too, an application our guide to Mendelian randomization covers step by step.

None of this changes the underlying discipline a research team needs. Bigger cohorts and faster classifiers still depend on standardized file formats, documented quality control, a defensible de-identification strategy, and a repository deposit a reviewer can actually check. Those practices are likely to matter more, not less, as the average genomic dataset attached to a manuscript keeps growing.

Conclusion

Large-scale genomic data rewards research teams that treat data management as part of the science rather than an administrative afterthought. A dataset built on standardized file formats, documented quality control, a realistic de-identification strategy, and a compliant repository deposit survives peer review faster and stays usable by other researchers years after the original manuscript is published. The programs cited throughout this guide, from the original 1000 Genomes Project through the All of Us Research Program’s release of more than 245,000 genomes, show that the same core practices scale from a single-site pilot study to a national cohort of a million participants (Auton et al., 2015; Bick et al., 2024). Getting the fundamentals right early remains the most reliable way to make sure a genomic finding survives contact with reviewers, replication attempts, and the researchers who will want to reuse the dataset long after the original study team has moved on.

Frequently Asked Questions

What file format should I use to share genomic variant data in my manuscript?

Deposit variant-level data in Variant Call Format, VCF, and specify the reference genome build plus the caller and version used to generate it, since the same VCF file interpreted against a different reference build can imply different, clinically relevant results.

Is de-identified genomic data the same as anonymized data?

No. Removing a name from a genetic sequence file reduces identifiability but does not eliminate it, because the variants themselves can be matched back to a person or their relatives through techniques such as familial searching. That is why funders require controlled access rather than open release for individual-level genomic data.

Do I need to register in dbGaP for every genomic study?

NIH’s Genomic Data Sharing Policy applies specifically to large-scale human genomic studies it funds, and those studies are expected to register in dbGaP and submit both data and a data use certification. Check the policy’s current scope on the NIH Office of Science Policy site before assuming a smaller pilot study is exempt.

How much smaller are CRAM files than BAM files for the same sequencing data?

CRAM typically cuts storage size by roughly 30 to 60 percent relative to BAM for the same whole-genome alignment data because it references the genome sequence itself instead of storing every base twice, though the exact savings depend on sequencing depth and the compression settings used.

What is the most common reason genomic manuscripts get sent back for revision over data reporting?

Missing or inconsistent methodological detail is the most frequent cause, typically an unspecified reference genome build, an unreported variant caller version, or a data availability statement that does not say whether access is open or controlled. All three are easy to fix before submission and slow to fix after a reviewer flags them.

Can machine learning replace manual variant curation in a research study?

Not entirely. Comparative work on UK Biobank whole-genome sequencing data found machine-learning classifiers could match or outperform conventional fine-mapping methods at flagging the most likely causal variant, but the underlying pipeline still needs the same quality control, version tracking, and orthogonal validation that any variant call requires before publication.

References

1. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi: 10.1038/nature15393
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795. doi: 10.1056/NEJMp1500523
3. Gottesman O, Kuivaniemi H, Tromp G, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med. 2013;15(10):761-771. doi: 10.1038/gim.2013.72
4. Bick AG, Metcalf GA, Mayo KR, et al. Genomic data in the All of Us Research Program. Nature. 2024;627(8003):340-346. doi: 10.1038/s41586-023-06957-x
5. Marshall CR, Chowdhury S, Taft RJ, et al. Best practices for the analytical validation of clinical whole-genome sequencing intended for the diagnosis of germline disease. NPJ Genom Med. 2021;5:47. doi: 10.1038/s41525-020-00154-9
6. Paltoo DN, Rodriguez LL, Feolo M, et al. Data use under the NIH GWAS Data Sharing Policy and future directions. Nat Genet. 2014;46(9):934-938. doi: 10.1038/ng.3062
7. Wong KM, Langlais K, Tobias GS, et al. The dbGaP data browser: a new tool for browsing dbGaP controlled-access genomic data. Nucleic Acids Res. 2017;45(D1):D819-D826. doi: 10.1093/nar/gkw1139
8. Mulder N, Adebamowo CA, Adebamowo SN, et al. Genomic research data generation, analysis and sharing – challenges in the African setting. Data Sci J. 2017;16. doi: 10.5334/dsj-2017-049
9. Takashima K, Maru Y, Mori S, Mano H, Noda T, Muto K. Ethical concerns on sharing genomic data including patients’ family members. BMC Med Ethics. 2018;19(1). doi: 10.1186/s12910-018-0310-5
10. Huang L, Krüger J, Sczyrba A. Analyzing large scale genomic data on the cloud with Sparkhit. Bioinformatics. 2018;34(9):1457-1465. doi: 10.1093/bioinformatics/btx808
11. Sng LMF, Kaphle A, O’Brien MJ, et al. Optimizing UK Biobank cloud-based research analysis platform to fine-map coronary artery disease loci in whole genome sequencing data. Sci Rep. 2025;15. doi: 10.1038/s41598-025-95286-2
12. Oliveira JS, Sant’Ana S, Santos M, Faria D. The Portuguese Beacon: sharing genomic variant data safely. Database (Oxford). 2026;2026. doi: 10.1093/database/baag012
13. National Human Genome Research Institute. The Cost of Sequencing a Human Genome. Updated 2021. genome.gov
14. National Institutes of Health, Office of Science Policy. NIH Genomic Data Sharing Policy. Updated August 2025. grants.nih.gov